The Conundrum of Clinical Trial Endpoints in Multiple Myeloma: We Don’t Have All the Time in the World

Blood ◽  
2011 ◽  
Vol 118 (12) ◽  
pp. 3205-3211 ◽  
Author(s):  
S. Vincent Rajkumar ◽  
Gösta Gahrton ◽  
P. Leif Bergsagel

Abstract In this Perspective, we summarize some of the most contentious issues surrounding diagnosis and treatment of myeloma. We outline how a fundamental clash of philosophies, cure versus control, may be at the heart of many of the controversies. From the very definition of the disease to risk stratification to the validity of current clinical trial endpoints, we highlight the major areas of debate and provide alternative viewpoints that have implications for trial design and interpretation, as well as clinical practice.


2021 ◽  
Author(s):  
Jie Wang ◽  
Sinan Lin ◽  
Jonathan Mark Brown ◽  
David van Wagoner ◽  
Claudio Fiocchi ◽  
...  

2005 ◽  
Vol 1 (4) ◽  
pp. 160-164 ◽  
Author(s):  
Daniel Corey ◽  
Hyung Woo Kim ◽  
Raul Salazar ◽  
Luis M. Gutierrez ◽  
Jorge Sánchez ◽  
...  

2014 ◽  
Vol 132 (1) ◽  
pp. 8-17 ◽  
Author(s):  
Thomas J. Herzog ◽  
Deborah K. Armstrong ◽  
Mark F. Brady ◽  
Robert L. Coleman ◽  
Mark H. Einstein ◽  
...  

2020 ◽  
Vol 5 (8) ◽  
pp. 1302-1305
Author(s):  
Salem Almaani ◽  
Udayan Bhatt ◽  
Cristina Arriens ◽  
Eloisa Bonfa ◽  
Maria Dall’Era ◽  
...  

2017 ◽  
Vol 147 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Thomas J. Herzog ◽  
Gwynn Ison ◽  
Ronald D. Alvarez ◽  
Sanjeeve Balasubramaniam ◽  
Deborah K. Armstrong ◽  
...  

2010 ◽  
Vol 182 (11) ◽  
pp. 1387-1397 ◽  
Author(s):  
Stephanie D. Davis ◽  
Margaret Rosenfeld ◽  
Gwendolyn S. Kerby ◽  
Lyndia Brumback ◽  
Margaret H. Kloster ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document